Search
Diosmetin
go.drugbank.com/drugs/DB11259ApprovedDiosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits [A27231].
Varespladib methyl
go.drugbank.com/drugs/DB05737InvestigationalVarespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.
Vinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalVinflunine ditartrate is an active ingredient in the EMA-authorised product Javlor for intravenous infusion. … In murine tumors and human tumor xenografts, vinflunine exhibits an antitumor efficacy than [DB00361], [DB00570], and [DB00541] [A31975].
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMeningococcal polysaccharide vaccine group A
go.drugbank.com/drugs/DB13889ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.
Meningococcal polysaccharide vaccine group C
go.drugbank.com/drugs/DB13890ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Daclizumab
go.drugbank.com/drugs/DB00111ApprovedInvestigationalWithdrawnThe human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. … 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de
Aleglitazar
go.drugbank.com/drugs/DB08915InvestigationalAleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist that works to inhibit bile acid synthesis. On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary b...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersLumefantrine co-artemether
go.drugbank.com/drugs/DB13085ApprovedInvestigationalWithdrawnThe combination is an effective and well-tolerated malaria treatment, providing high cure rates even in areas of multi-drug resistance. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesILY101
go.drugbank.com/drugs/DB05059InvestigationalILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on d...